Eli Lilly to Take Over Development of Diabetes Drug


As per an agreement initially entered into in 2010, Eli Lilly will pay Transition Therapeutics $7 million to exercise its right to take development and commercialization ownership of the type 2 diabetes drug candidate TT-401, Transition Therapeutics announced today.

Transition Therapeutics also announced that the original agreement with Eli Lilly relating to TT-401 has been amended. Eli Lilly will assume all costs for testing and commercialization, however, Transition Therapeutics has agreed to make a total of $14 million in payments to Eli Lilly in three separate installments during TT-401's phase 2 clinical study trials, according to the press release.

Should the type 2 diabetes and obesity drug TT-401 successfully make it to the commercialization stage, Eli Lilly has also agreed to make milestone payments to Transition Therapeutics totaling an estimated $240 million, in addition to royalty payments on product and related compound sales.

David Moller, Eli Lilly's vice president of endocrine and cardiovascular research and clinical investigation, said in a statement, "We are encouraged by the early data seen to date with TT-401, and are pleased by the efficient and thorough process by which Transition Therapeutics conducted the Phase 1 studies."


The article Eli Lilly to Take Over Development of Diabetes Drug originally appeared on Fool.com.

Fool contributor Tim Brugger has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Originally published